Date: | 2018 Aug |
PMID: | |
Category: | 2 |
Authors: | Isabelle Scheers 1 2, Joseph J Palermo 3, Steven Freedman 4, Michael Wilschanski 5, Uzma Shah 6, Maisam Abu-El-Haija 3, Bradley Barth 7, Douglas S Fishman 8, Cheryl Gariepy 9, Matthew J Giefer 10, Melvin B Heyman 11, Ryan W Himes 8, Sohail Z Husain 12, Tom K Lin 3, Quin Liu 13, Mark Lowe 14, Maria Mascarenhas 15, Veronique Morinville 16, Chee Y Ooi 17, Emily R Perito 11, David A Piccoli 15, John F Pohl 18, Sarah J Schwarzenberg 19, David Troendle 7, Steven Werlin 20, Bridget Zimmerman 21, Aliye Uc 21, Tanja Gonska 1 |
Abstract: |
|
Objectives: Autoimmune pancreatitis (AIP) represents a complex immune-mediated pancreas disorder. Pediatric AIP (P-AIP) is rare. We have recently summarized the characteristic features of P-AIP. We now aim to develop recommendation statements to standardize the diagnostic and therapeutic approach to P-AIP and facilitate future research in the field.
Methods: A panel of pediatric gastroenterologists participating in the International Study Group of Pediatric Pancreatitis: In search for a cuRE was formed to discuss and then vote on 15 recommendation statements. A consensus of at least 80% was obtained following 3 voting rounds and revision of the statements.
Results: We have now generated 15 statements to help standardize the approach to diagnosis and management of P-AIP.
Conclusions: The first P-AIP recommendation statements developed by the International Study Group of Pediatric Pancreatitis: In search for a cuRE group are intended to bring standardization to the diagnosis and treatment of this rare childhood disorder. These statements may help guide a uniform approach to patient care and facilitate future research studies.
Acknowledgements:
The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute, the National Institute of Health, or the National Institute of Diabetes and Digestive and Kidney Diseases.
The Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) Research Consortia is supported and funded by grants from the National Cancer Institute and the National Institute of Diabetes and Digestive and Kidney Diseases under the following award numbers:
Project Number: | Awardee Organization |
U01DK108326 | Baylor College of Medicine |
U01DK108314 | Cedars-Sinai Medical Center |
U01DK108332 | Indiana University |
U01DK108323 | Kaiser Foundation Research Institute |
U01DK108288 | Mayo Clinic |
U01DK108327 | Ohio State University |
U01DK108300 | Stanford University |
U01DK108320 | University of Florida |
U01DK108306 | University of Pittsburgh |
U01DK108328 | University of Texas MD Anderson Cancer Center |
Comments